MiSaver stem cell therapy - Honya Medical
Alternative Names: MiSaver® stem cell therapyLatest Information Update: 29 Sep 2025
At a glance
- Originator HONYA Medical
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Myocardial infarction
Most Recent Events
- 21 Aug 2025 HONYA Medical plans a phase II trial for Myocardial Infarction in Taiwan (IV) in October 2025 (NCT07134712)
- 04 May 2023 Honya Medical completes the Phase-I/II clinical trials in Myocardial infarction in Taiwan (IV) (NCT04050163)
- 26 Jan 2021 Phase-I/II clinical trials in Myocardial infarction in Taiwan (IV) (NCT04050163)